港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

拨康视云-B

4.330

-0.130-2.91%

成交量：23.40万

成交额：101.80万

市值：36.59亿

市盈率：-2.67

高：4.450

开：4.450

低：4.300

收：4.460

52周最高：9.740

52周最低：3.940

股本：8.45亿

香港流通股本：8.45亿

量比：0.97

换手率：0.03%

股息：- -

股息率：- -

每股收益(LYR):-1.621

净资产收益率：--

总资产收益率：-44.38%

市净率：-1.43

市盈率(LYR):-2.67

市销率: 45.95

数据加载中...

总览公司新闻资讯公告

拨康视云-B(02592.HK)预计7月3日上市引入富策控股及Reynold Lemkins作为基石

拨康视云-B(02592.HK)预计7月3日上市引入富策控股及Reynold Lemkins作为基石

拨康视云-B(02592.HK)6月24日起招股发售价将为每股10.10港元

拨康视云-B(02592.HK)6月24日起招股发售价将为每股10.10港元

新股预览：拨康视云-B(2592.HK)

光大新鸿基

拨康视云通过港交所聆讯，计划募资用于核心产品研发等

新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯，三年累计亏损2.95亿美元

智通财经网

新股消息眼科生物科技公司拨康视云通过港交所聆讯三年累计亏损2.95亿美元

新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯三年累计亏损2.95亿美元

新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯三年累计亏损2.95亿美元

智通财经网

【新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯三年累计亏损2.95亿美元】智通财经APP获悉，据港交所6月20

拨康视云“四闯”港交所背后：四年累亏3.3亿美元，股东“内耗”、产品商业化困局待解

拨康视云“四闯”港交所背后：四年累亏3.3亿美元

拨康视云“四闯”港交所背后：四年累亏3.3亿美元，股东“内耗”、产品商业化困局待解

Cloudbreak Pharma Inc.（拨康视云）通过港交所上市聆讯

每日经济新闻

新股解读|核心产品CBT-001商业化还要等多久？拨康视云3年烧钱21亿再战港股

拨康视云-B，递交招股书，拟赴香港上市 | 未盈利生物科技.IPO上市

港澳IPO上市

新股消息眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元

新股消息 | 眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元

新股消息 | 眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02592/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":4.33,"timestamp":1763366895008,"preClose":4.46,"halted":0,"volume":234000,"delay":0,"floatShares":844999999,"shares":844999999,"eps":-1.6212360345511228,"marketStatus":"未开盘","change":-0.13,"latestTime":"11-17 16:08:15","open":4.45,"high":4.45,"low":4.3,"amount":1017990,"amplitude":0.033632,"askPrice":4.4,"askSize":1000,"bidPrice":4.33,"bidSize":13500,"shortable":3,"etf":0,"ttmEps":-1.309552872392533,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":4.46,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.9653465340560975,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":844999999,"roa":"-44.38%","roe":"--","lyrEps":-1.621236,"volumeRatio":0.9653465340560975,"shares":844999999,"dividePrice":0,"high":4.45,"amplitude":0.033632,"preClose":4.46,"low":4.3,"week52Low":3.94,"pbRate":"-1.43","psRate":"45.95","week52High":9.74,"institutionHeld":0,"latestPrice":4.33,"committee":0.862069,"eps":-1.6212360345511228,"divideRate":0,"volume":234000,"delay":0,"ttmEps":-1.309552872392533,"open":4.45,"prevYearClose":10.1,"prevWeekClose":4.46,"prevMonthClose":4.71,"prevQuarterClose":4.51,"fiveDayClose":4.7,"twentyDayClose":4.78,"sixtyDayClose":5.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2025-11-14","current":-3.307012,"percent":0.365591,"low":-13.478827,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"high":-5.348116,"avg":-8.53714,"sd":3.119566,"marketCap":3741462218},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218}],"updateTime":1763377323318},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545423036","title":"拨康视云-B(02592.HK)预计7月3日上市 引入富策控股及Reynold Lemkins作为基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423036","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423036?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:48","pubTimestamp":1750718886,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2Q40O7405568W0A.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2Q40O7405568W0A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545342376","title":"拨康视云-B(02592.HK)预计7月3日上市 引入富策控股及Reynold Lemkins作为基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2545342376","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545342376?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:47","pubTimestamp":1750718838,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨拨康视云-B发布公告，公司拟全球发售6058.2万股股份，中国香港发售股份605.85万股，国际发售股份5452.35万股；2025年6月24日至6月27日招股；发售价将为每股发售股份10.10港元，每手买卖单位为500股，建银国际及华泰国际为联席保荐人；预期股份将于2025年7月3日开始在联交所买卖。集团拥有两款核心产品，均为自主开发。基石投资者包括富策控股有限公司及The Reynold Lemkins Group  Limited。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24064751250137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1576","02592","BK1141","03347"],"gpt_icon":0},{"id":"2545423030","title":"拨康视云-B(02592.HK)6月24日起招股 发售价将为每股10.10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423030","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423030?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:41","pubTimestamp":1750718471,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2Q3K3KR05198ETO.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2Q3K3KR05198ETO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545423902","title":"拨康视云-B(02592.HK)6月24日起招股 发售价将为每股10.10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423902","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423902?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:37","pubTimestamp":1750718256,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨拨康视云-B(02592.HK)发布公告，公司拟全球发售6058.2万股股份，中国香港发售股份605.85万股，国际发售股份5452.35万股；2025年6月24日至6月27日招股；发售价将为每股发售股份10.10港元，每手买卖单位为500股，建银国际及华泰国际为联席保荐人；预期股份将于2025年7月3日开始在联交所买卖。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24063751250119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545476690","title":"新股预览：拨康视云-B(2592.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545476690","media":"光大新鸿基","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545476690?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 00:00","pubTimestamp":1750694400,"startTime":"0","endTime":"0","summary":"公司的历史可追溯至2015年集团成立之时。公司拥有两款核心产品，均为自主开发。预计将能治疗各种中度至重度翼状胬肉。根据弗若斯特沙利文报告，目前全球并无获批的药物用来治疗翼状胬肉，翼状胬肉的现有治疗选择是手术切除。一旦CBT-001 获得批准，有望成为全球首款用来治疗翼状胬肉的药物，通过早期非侵入性治疗控制翼状胬肉的发展，从而减少或推迟手术切除的需要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624115206a4bab8a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624115206a4bab8a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":0},{"id":"2545496670","title":"拨康视云通过港交所聆讯，计划募资用于核心产品研发等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545496670","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545496670?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 16:10","pubTimestamp":1750666208,"startTime":"0","endTime":"0","summary":"来源|贝多财经6月20日，CLOUDBREAK PHARMA INC.通过港交所上市聆讯，并披露了聆讯后招股书。本次报考上市，拨康视云计划将募资金额用于核心产品CBT-001的持续临床研发活动以及注册备案及获批后研究所需资金；持续临床研发活动，包括研发人员及研发活动的成本及开支，以及核心产品CBT-009的注册备案的所需资金等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623163031a4b8822a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623163031a4b8822a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348814723.USD","IE00BZ08YS42.EUR","LU0084288322.USD","LU0898667661.SGD","IE00BZ08YT58.USD","LU0359201612.USD","LU0370786039.SGD","IE00BZ08YR35.GBP","LU0348827113.USD","SG9999001093.SGD","LU1242518931.SGD","LU0048597586.USD","LU0540923850.HKD","LU0456846285.SGD","LU0348735423.USD","LU0417516738.SGD","LU0072913022.USD","02592","LU1366334578.USD","LU0607220059.USD","LU0348825331.USD","HEXmain","LU0762540952.USD","LU1044874839.SGD","LU1993786604.SGD","80388","LU1105468828.SGD","LU0831093199.SGD","LU0043850808.USD","LU0594300179.USD","LU2226246903.HKD","LU0196878994.USD","LU1807302812.USD","LU0572944931.SGD","LU0648948544.HKD","LU0577902538.SGD","LU0577902371.SGD","LU0650527681.SGD","LU0149721374.USD","LU1282649067.USD","HKXCY","LU0516422440.USD","LU1282648689.USD","LU0918141887.USD","LU0762541174.USD","LU1048588211.SGD","00388","LU0164880469.USD","LU1282649141.HKD","LU0359201885.HKD","LU0048580855.USD"],"gpt_icon":1},{"id":"2545480796","title":"新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯，三年累计亏损2.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545480796","media":"智通财经网","labels":["dataReport","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545480796?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 11:17","pubTimestamp":1750562275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所6月20日披露，CLOUDBREAK PHARMA INC.通过港交所上市聆讯，建银国际、华泰国际为其联席保荐人。招股书披露，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。财务方面，于往绩记录期，公司产生净亏损。2022年度、2023年度及2024年度，拨康视云年内亏损分别约为0.67亿美元、1.29亿美元、0.99亿美元，此外，2024年收益约为1000万美元。","market":"sh","thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308106.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02592"],"gpt_icon":0},{"id":"2545387234","title":"新股消息   眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545387234","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545387234?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 10:07","pubTimestamp":1750558034,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2LAJUUE0519QIKK.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2LAJUUE0519QIKK.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545082480","title":"新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545082480","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545082480?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 09:10","pubTimestamp":1750554606,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2L7BBM705198UNI.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2L7BBM705198UNI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545802904","title":"新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545802904","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545802904?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 09:01","pubTimestamp":1750554090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所6月20日披露，CLOUDBREAK PHARMA INC.通过港交所上市聆讯，建银国际、华泰国际为其联席保荐人。招股书披露，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。财务方面，于往绩记录期，公司产生净亏损。2022年度、2023年度及2024年度，拨康视云年内亏损分别约为0.67亿美元、1.29亿美元、0.99亿美元，此外，2024年收益约为1000万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062209031197898205&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062209031197898205&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1131","00388","80388"],"gpt_icon":1},{"id":"2545480213","title":"【新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元】智通财经APP获悉，据港交所6月20","url":"https://stock-news.laohu8.com/highlight/detail?id=2545480213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545480213?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 09:01","pubTimestamp":1750554090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HEXmain","159837","INC","02592"],"gpt_icon":0},{"id":"2545481638","title":"拨康视云“四闯”港交所背后：四年累亏3.3亿美元，股东“内耗”、产品商业化困局待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2545481638","media":"华夏时报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545481638?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 00:01","pubTimestamp":1750521670,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2K7U75T0512D03F.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2K7U75T0512D03F.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545485360","title":"拨康视云“四闯”港交所背后：四年累亏3.3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545485360","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545485360?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 18:31","pubTimestamp":1750501881,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2JL29ST05568W0A.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2JL29ST05568W0A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545483120","title":"拨康视云“四闯”港交所背后：四年累亏3.3亿美元，股东“内耗”、产品商业化困局待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2545483120","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545483120?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 17:41","pubTimestamp":1750498860,"startTime":"0","endTime":"0","summary":"但由于尚未有药品上市实现商业化，公司一直处于亏损状态，四年累计亏损3.3亿美元。拨康视云进入成立的第九个年头，但公司产品仍未实现商业化，导致其只能依靠融资来维持运营。招股书显示，拨康视云在上市前的股东架构中，股东数量多达30个。从上述招股书披露来看，公司产品均处于临床试验阶段。与此同时，拨康视云在招股书中披露，预计2025年亏损净额将增加，主要是因为与将作出的以股份为基础的付款增加有关的员工成本预期增加等。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-06-21/doc-infavpze5139902.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-21/doc-infavpze5139902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HEXmain","02592"],"gpt_icon":0},{"id":"2545488293","title":"Cloudbreak Pharma Inc.（拨康视云）通过港交所上市聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2545488293","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545488293?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 16:35","pubTimestamp":1750494907,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2JEDFHE0512B07B.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2JEDFHE0512B07B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2543537676","title":"新股解读|核心产品CBT-001商业化还要等多久？拨康视云3年烧钱21亿再战港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2543537676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543537676?lang=zh_cn&edition=fundamental","pubTime":"2025-06-16 18:13","pubTimestamp":1750068781,"startTime":"0","endTime":"0","summary":"据招股书，拨康视云一般及行政开支由2023年的0.11亿美元减少约180万美元或15.9%至2024年的约950万美元。CBT-001截至最后实际可行日期，并无临时数据可供分析。弗若斯特沙利文报告显示，CBT-001对应的全球治疗翼状胬肉药物的市场规模预计将于2027年达到273.4百万美元及于2032年达到2,529.4百万美元，复合年增长率为56.0%。然而，作为距离商业化最近的产品CBT-001，拨康视云已将部分权益让渡给远大医药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK4090","YANG","CBT","HSCEI","BK4614","HSTECH"],"gpt_icon":1},{"id":"2543139266","title":"拨康视云-B，递交招股书，拟赴香港上市 | 未盈利生物科技.IPO上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2543139266","media":"港澳IPO上市","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543139266?lang=zh_cn&edition=fundamental","pubTime":"2025-06-15 21:37","pubTimestamp":1749994620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NTA3NDA2MA==&mid=2247502333&idx=2&sn=fe4c5036cac8e7d12e8014a87977047e&chksm=ebd191138188ae7db3c2a8937bddb4a3b1545aa77b12084504c65adab87111f87c6788fc9973&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02592"],"gpt_icon":0},{"id":"2542581692","title":"新股消息   眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581692","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542581692?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 19:53","pubTimestamp":1749642806,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K1Q1PE0P0519QIKK.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K1Q1PE0P0519QIKK.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2542589196","title":"新股消息 | 眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542589196","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542589196?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 19:25","pubTimestamp":1749641115,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K1Q05QEJ05198UNI.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K1Q05QEJ05198UNI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2542586765","title":"新股消息 | 眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542586765","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542586765?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 19:09","pubTimestamp":1749640178,"startTime":"0","endTime":"0","summary":"拨康视云首家主要营运实体Cloudbreak USA于2015年9月在美国注册成立及公司于2020年11月在开曼群岛注册成立。潜在市场及竞争格局方面，全球眼科药物市场规模由2019年的337亿美元增加至2023年的396亿美元，复合年增长率为4.1%。业绩方面，于2022年度、2023年度及2024年度，拨康视云年内亏损分别约为0.67亿美元、1.29亿美元、0.99亿美元，此外，2024年收益约为1000万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1304061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","159837"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":81,"code":"91000000","status":"200"}]}}